{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:54:40Z","timestamp":1775282080065,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Essential thrombocytosis (ET) is a\u00a0rare haematological malignancy, with an incidence rate of 1.5\u20132.5\/100,000 per year. For many patients with ET the first manifestation of their underlying disease is a\u00a0thrombotic or haemorrhagic complication. A\u00a0recent retrospective study revealed an incidence rate of at least 2.1% in people under 40\u00a0years presenting with an acute coronary syndrome, although the diagnosis was initially missed in all cases. Thus, cardiologists face a\u00a0much higher than average incidence rate of ET in their daily practice, but seem insufficiently aware of the disease. The current review summarises symptoms, (differential) diagnosis, complications and treatment considerations of ET of relevance for a\u00a0cardiologist. Typical symptoms, besides thrombosis and haemorrhage, include erythromelalgia and aquagenic pruritus, while platelets &gt;\u202f450\u202f\u00d7\u200910<jats:sup>9<\/jats:sup>\/l are a\u00a0diagnostic for ET once other myeloproliferative neoplasms, secondary and spurious thrombocytosis have been excluded. With regard to treatment, timing of revascularisation depends on the presence of ischaemia and concurrent platelet counts. In the presence of ischaemia, revascularisation should not be delayed and adequate platelet counts can be achieved by platelet apheresis. In the absence of ischaemia, revascularisation can be delayed until adequate platelet counts have been achieved by cytoreductive therapies. Cardiologists should be aware of\/screen for possible ET.<\/jats:p>","DOI":"10.1007\/s12471-023-01757-4","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:39:28Z","timestamp":1675989568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a\u00a0cardiologist"],"prefix":"10.1007","author":[{"given":"R. S.","family":"Kuipers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Virmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"1757_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1046\/j.1365-2796.1998.00314.x","volume":"244","author":"C Rossi","year":"1998","unstructured":"Rossi\u00a0C, Randi\u00a0ML, Zerbinati\u00a0P, Rinaldi\u00a0V, Girolami\u00a0A. Acute coronary disease in essential thrombocythemia and polycythemia vera. J\u00a0Intern Med. 1998;244:49\u201353.","journal-title":"J Intern Med"},{"key":"1757_CR2","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.1975.03240210031015","volume":"231","author":"MD Cheitlin","year":"1975","unstructured":"Cheitlin\u00a0MD, McAllister\u00a0HA, de Castro\u00a0CM. Myocardial infarction without atherosclerosis. JAMA. 1975;231:951\u20139.","journal-title":"JAMA"},{"key":"1757_CR3","first-page":"e32638","volume":"14","author":"L Kok","year":"2022","unstructured":"Kok\u00a0L, Taverne\u00a0LF, Verbeek\u00a0EC, et al. Essential thrombocytosis in patients <\u202f40\u00a0years old with acute coronary syndromes: a\u00a0not so uncommon underlying diagnosis often overlooked. Cureus. 2022;14:e32638.","journal-title":"Cureus"},{"key":"1757_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.repc.2018.09.014","volume":"38","author":"B Cengiz","year":"2019","unstructured":"Cengiz\u00a0B, Aytekin\u00a0V, Bildirici\u00a0U, et\u00a0al. A rare cause of acute coronary syndromes in young adults\u2014myeloproliferative neoplasms: a case series. Rev Port Cardiol (Engl Ed). 2019;38:613\u20137.","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"1757_CR5","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui\u00a0T, Finazzi\u00a0G, Carobbio\u00a0A, et al. Development and validation of an international prognostic score of thrombosis in world health organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128\u201333. quiz 5252.","journal-title":"Blood"},{"key":"1757_CR6","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi\u00a0A, Barbui\u00a0T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:1599\u2013613.","journal-title":"Am J Hematol"},{"key":"1757_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","volume":"21","author":"A Alvarez-Larr\u00e1n","year":"2007","unstructured":"Alvarez-Larr\u00e1n\u00a0A, Cervantes\u00a0F, Bellosillo\u00a0B, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126\u00a0patients. Leukemia. 2007;21:1218\u201323.","journal-title":"Leukemia"},{"key":"1757_CR8","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio\u00a0A, Thiele\u00a0J, Passamonti\u00a0F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891\u00a0patients. Blood. 2011;117:5857\u20139.","journal-title":"Blood"},{"key":"1757_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V De Stefano","year":"2008","unstructured":"De Stefano\u00a0V, Za\u00a0T, Rossi\u00a0E, et\u00a0al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93:372\u201380.","journal-title":"Haematologica"},{"key":"1757_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0002-8703(91)91019-J","volume":"122","author":"MG Scheffer","year":"1991","unstructured":"Scheffer\u00a0MG, Michiels\u00a0JJ, Simoons\u00a0ML, Roelandt\u00a0JR. Thrombocythemia and coronary artery disease. Am Heart\u00a0J. 1991;122:573\u20136.","journal-title":"Am Heart J"},{"key":"1757_CR11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.7326\/0003-4819-102-4-466","volume":"102","author":"JJ Michiels","year":"1985","unstructured":"Michiels\u00a0JJ, Abels\u00a0J, Steketee\u00a0J, van Vliet\u00a0HH, Vuzevski\u00a0VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 1985;102:466\u201371.","journal-title":"Ann Intern Med"},{"key":"1757_CR12","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/jth.14588","volume":"17","author":"C Le Gall-Ianotto","year":"2019","unstructured":"Le Gall-Ianotto\u00a0C, Le Calloch\u00a0R, Couturier\u00a0M\u2011A, et al. Aquagenic pruritus in essential thrombocythemia is associated with a\u00a0higher risk of thrombosis. J\u00a0Thromb Haemost. 2019;17:1950\u20135.","journal-title":"J Thromb Haemost"},{"key":"1757_CR13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ajcp\/84.2.180","volume":"84","author":"RB Davis","year":"1985","unstructured":"Davis\u00a0RB. Acute thrombotic complications of myeloproliferative disorders in young adults. Am J Clin Pathol. 1985;84:180\u20135.","journal-title":"Am J Clin Pathol"},{"key":"1757_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4065\/76.1.22","volume":"76","author":"A Tefferi","year":"2001","unstructured":"Tefferi\u00a0A, Fonseca\u00a0R, Pereira\u00a0DL, Hoagland\u00a0HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001;76:22\u20138.","journal-title":"Mayo Clin Proc"},{"key":"1757_CR15","doi-asserted-by":"publisher","first-page":"l4183","DOI":"10.1136\/bmj.l4183","volume":"366","author":"A Mathur","year":"2019","unstructured":"Mathur\u00a0A, Samaranayake\u00a0S, Storrar\u00a0NP, Vickers\u00a0MA. Investigating thrombocytosis. BMJ. 2019;366:l4183.","journal-title":"BMJ"},{"key":"1757_CR16","unstructured":"Rokkam VR, Kotagiri R. Secondary thrombocytosis. 2022. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560810\/. Accessed 3 Apr 2022."},{"key":"1757_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bcmd.2005.12.031","volume":"36","author":"PE Petrides","year":"2006","unstructured":"Petrides\u00a0PE, Siegel\u00a0F. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. Blood Cells Mol Dis. 2006;36:379\u201384.","journal-title":"Blood Cells Mol Dis"},{"key":"1757_CR18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2257.2006.00870.x","volume":"29","author":"M Zandecki","year":"2007","unstructured":"Zandecki\u00a0M, Genevieve\u00a0F, Gerard\u00a0J, Godon\u00a0A. Spurious counts and spurious results on haematology analysers: a\u00a0review. Part I: platelets. Int J Lab Hematol. 2007;29:4\u201320.","journal-title":"Int J Lab Hematol"},{"key":"1757_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4103\/2229-516X.165372","volume":"5","author":"GB Madaan","year":"2015","unstructured":"Madaan\u00a0GB, Jairajpuri\u00a0ZS, Hajini\u00a0FF, Jetley\u00a0S. Postoperative thrombocytosis: an unusual case report. Int J Appl Basic Med Res. 2015;5:225\u20137.","journal-title":"Int J Appl Basic Med Res"},{"key":"1757_CR20","first-page":"215","volume":"89","author":"T Barbui","year":"2004","unstructured":"Barbui\u00a0T, Barosi\u00a0G, Grossi\u00a0A, et\u00a0al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian society of hematology, the Italian society of experimental hematology and the Italian group for bone marrow transplantation. Haematologica. 2004;89:215\u201332.","journal-title":"Haematologica"},{"key":"1757_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","volume":"128","author":"MA Elliott","year":"2005","unstructured":"Elliott\u00a0MA, Tefferi\u00a0A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275\u201390.","journal-title":"Br J Haematol"},{"key":"1757_CR22","first-page":"383","volume":"9","author":"A Derks","year":"2001","unstructured":"Derks\u00a0A, Bloemer\u00a0MH. Essential thrombocythaemia as cause of myocardial infarction. Neth Heart\u00a0J. 2001;9:383\u20135.","journal-title":"Neth Heart J"},{"key":"1757_CR23","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S0140-6736(84)91217-0","volume":"2","author":"P Douste-Blazy","year":"1984","unstructured":"Douste-Blazy\u00a0P, Taudou\u00a0MJ, Delay\u00a0M, et al. Essential thrombocythaemia and recurrent myocardial infarction. Lancet. 1984;2:992.","journal-title":"Lancet"},{"key":"1757_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12928-015-0347-z","volume":"31","author":"I Khaheshi","year":"2016","unstructured":"Khaheshi\u00a0I, Memaryan\u00a0M, Taherkhani\u00a0M, Serati\u00a0A, Movahed\u00a0MR. Acute ST-segment elevation myocardial infarction as the first manifestation of essential thrombocytosis successfully treated with thrombectomy alone. Cardiovasc Interv Ther. 2016;31:275\u20138.","journal-title":"Cardiovasc Interv Ther"},{"key":"1757_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4330\/wjc.v3.i8.278","volume":"3","author":"C-W Cheng","year":"2011","unstructured":"Cheng\u00a0C\u2011W, Hung\u00a0M\u2011J. Coronary spasm-related acute myocardial infarction in a\u00a0patient with essential thrombocythemia. World J Cardiol. 2011;3:278\u201380.","journal-title":"World J Cardiol"},{"key":"1757_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/0167-5273(93)90158-D","volume":"41","author":"KK Koh","year":"1993","unstructured":"Koh\u00a0KK, Cho\u00a0SK, Kim\u00a0SS, Oh\u00a0BH, Lee\u00a0YW. Coronary vasospasm, multiple coronary thrombosis, unstable angina and essential thrombocytosis. Int J Cardiol. 1993;41:168\u201370.","journal-title":"Int J Cardiol"},{"key":"1757_CR27","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/0002-9343(79)90800-3","volume":"67","author":"R Virmani","year":"1979","unstructured":"Virmani\u00a0R, Popovsky\u00a0MA, Roberts\u00a0WC. Thrombocytosis, coronary thrombosis and acute myocardial infarction. Am J Med. 1979;67:498\u2013506.","journal-title":"Am J Med"},{"key":"1757_CR28","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/1097-0142(19880615)61:12<2487::AID-CNCR2820611217>3.0.CO;2-T","volume":"61","author":"R Hehlmann","year":"1988","unstructured":"Hehlmann\u00a0R, Jahn\u00a0M, Baumann\u00a0B, K\u00f6pcke\u00a0W. Essential thrombocythemia. Clinical characteristics and course of 61\u00a0cases. Cancer. 1988;61:2487\u201396.","journal-title":"Cancer"},{"key":"1757_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/IMCRJ.S217568","volume":"12","author":"M-C Soucy-Gigu\u00e8re","year":"2019","unstructured":"Soucy-Gigu\u00e8re\u00a0M\u2011C, Turgeon\u00a0PY, S\u00e9n\u00e9chal\u00a0M. What cardiologists should know about essential thrombocythemia and acute myocardial infarction: report of two cases and advanced heart failure therapies considerations. Int Med Case Rep\u00a0J. 2019;12:253\u20139.","journal-title":"Int Med Case Rep J"},{"key":"1757_CR30","first-page":"1","volume":"22","author":"V Gangadharan","year":"2014","unstructured":"Gangadharan\u00a0V, Ticku\u00a0J, Kasi\u00a0V. Acute myocardial infarction in a\u00a021-year-old male due to essential thombocytosis. Cath Lab Digest. 2014;22:1\u20137.","journal-title":"Cath Lab Digest"},{"key":"1757_CR31","doi-asserted-by":"publisher","first-page":"102476","DOI":"10.1155\/2015\/102476","volume":"2015","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch\u00a0HC, Bj\u00f8rn\u00a0ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015:102476.","journal-title":"Mediators Inflamm"},{"key":"1757_CR32","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1182\/bloodadvances.2019000655","volume":"3","author":"J Hong","year":"2019","unstructured":"Hong\u00a0J, Lee\u00a0JH, Byun\u00a0JM, et\u00a0al. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. Blood Adv. 2019;3:3700\u20138.","journal-title":"Blood Adv"},{"key":"1757_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11899-011-0107-9","volume":"7","author":"MN Kundranda","year":"2012","unstructured":"Kundranda\u00a0MN, Tibes\u00a0R, Mesa\u00a0RA. Transformation of a\u00a0chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? Curr Hematol Malig Rep. 2012;7:78\u201386.","journal-title":"Curr Hematol Malig Rep"},{"key":"1757_CR34","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","volume":"118","author":"F Cervantes","year":"2002","unstructured":"Cervantes\u00a0F, Alvarez-Larr\u00e1n\u00a0A, Talarn\u00a0C, G\u00f3mez\u00a0M, Montserrat\u00a0E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a\u00a0series of 195\u00a0patients. Br J Haematol. 2002;118:786\u201390.","journal-title":"Br J Haematol"},{"key":"1757_CR35","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi\u00a0A, Guglielmelli\u00a0P, Larson\u00a0DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313. quiz 2615.","journal-title":"Blood"},{"key":"1757_CR36","doi-asserted-by":"publisher","first-page":"E464","DOI":"10.1002\/ajh.26377","volume":"96","author":"CJ Smith","year":"2021","unstructured":"Smith\u00a0CJ, Thomas\u00a0JW, Ruan\u00a0G, et al. A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: comparison with data from a\u00a0Mayo Clinic single institutional series. Am J Hematol. 2021;96:E464\u20138.","journal-title":"Am J Hematol"},{"key":"1757_CR37","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","volume":"32","author":"AR Landtblom","year":"2018","unstructured":"Landtblom\u00a0AR, Bower\u00a0H, Andersson\u00a0TM\u2011L, et al. Second malignancies in patients with myeloproliferative neoplasms: a\u00a0population-based cohort study of 9379\u00a0patients. Leukemia. 2018;32:2203\u201310.","journal-title":"Leukemia"},{"key":"1757_CR38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/ajh.26067","volume":"96","author":"N Gangat","year":"2021","unstructured":"Gangat\u00a0N, Tefferi\u00a0A. Myeloproliferative neoplasms and pregnancy: overview and practice recommendations. Am J Hematol. 2021;96:354\u201366.","journal-title":"Am J Hematol"},{"key":"1757_CR39","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo\u00a0S, Finazzi\u00a0G, Ruggeri\u00a0M, et\u00a0al. Hydroxyurea for patients with essential thrombocythemia and a\u00a0high risk of thrombosis. N\u00a0Engl J Med. 1995;332:1132\u20137.","journal-title":"N Engl J Med"},{"key":"1757_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison\u00a0CN, Campbell\u00a0PJ, Buck\u00a0G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N\u00a0Engl J Med. 2005;353:33\u201345.","journal-title":"N Engl J Med"},{"key":"1757_CR41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3324\/haematol.12604","volume":"93","author":"R Landolfi","year":"2008","unstructured":"Landolfi\u00a0R, Di Gennaro\u00a0L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93:331\u20135.","journal-title":"Haematologica"},{"key":"1757_CR42","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/j.1538-7836.2009.03469.x","volume":"7","author":"G Campo","year":"2009","unstructured":"Campo\u00a0G, Valgimigli\u00a0M, Carletti\u00a0R, Fileti\u00a0L, Ferrari\u00a0R. Long-term outcome after percutaneous coronary intervention in patients with essential thrombocythemia. J\u00a0Thromb Haemost. 2009;7:1235\u20138.","journal-title":"J Thromb Haemost"},{"key":"1757_CR43","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/09537104.2019.1665640","volume":"31","author":"Y Zheng","year":"2020","unstructured":"Zheng\u00a0Y, Xu\u00a0T, Chen\u00a0L, Lin\u00a0S, Chen\u00a0S. Percutaneous coronary intervention in patients with essential thrombocythemia: case reports and literature review. Platelets. 2020;31:815\u20139.","journal-title":"Platelets"},{"key":"1757_CR44","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/BF03091797","volume":"18","author":"BE Sch\u00f6lzel","year":"2010","unstructured":"Sch\u00f6lzel\u00a0BE, Endeman\u00a0H, Dewilde\u00a0W, Yilmaz\u00a0A, de Weerdt\u00a0O, Ten Berg\u00a0JM. Cardiac surgery in a\u00a0patient with essential thrombocythemia: a\u00a0case report. Neth Heart\u00a0J. 2010;18:378\u201380.","journal-title":"Neth Heart J"},{"key":"1757_CR45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jccase.2013.08.001","volume":"8","author":"I Bo\u0161njak","year":"2013","unstructured":"Bo\u0161njak\u00a0I, Selthofer-Relati\u0107\u00a0K, Peri\u0161a\u00a0V, Steiner\u00a0R. Therapeutic dilemmas in the treatment of acute coronary syndrome as manifestation of essential thrombocythaemia. J\u00a0Cardiol Cases. 2013;8:168\u201371.","journal-title":"J Cardiol Cases"},{"key":"1757_CR46","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1161\/01.CIR.0000086347.31341.F9","volume":"108","author":"R Mehran","year":"2003","unstructured":"Mehran\u00a0R, Aymong\u00a0ED, Ashby\u00a0DT, et al. Safety of an aspirin-alone regimen after intracoronary stenting with a\u00a0heparin-coated stent: final results of the HOPE (HEPACOAT and an antithrombotic regimen of aspirin alone) study. Circulation. 2003;108:1078\u201383.","journal-title":"Circulation"},{"key":"1757_CR47","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1016\/j.amjcard.2014.01.313","volume":"113","author":"Z I\u015f\u0131lak","year":"2014","unstructured":"I\u015f\u0131lak\u00a0Z, Tezcan\u00a0M, Atalay\u00a0M, Karde\u015fo\u011flu\u00a0E. PP-285 Acute myocardial infarction and subsequently in-stent thrombosis associated with occult essential thrombocytosis. Am J Cardiol. 2014;113:S120\u20131.","journal-title":"Am J Cardiol"},{"key":"1757_CR48","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/(SICI)1097-0304(199812)45:4<428::AID-CCD19>3.0.CO;2-E","volume":"45","author":"T Turgut","year":"1998","unstructured":"Turgut\u00a0T, Harjai\u00a0KJ, Edupuganti\u00a0R, et al. Acute coronary occlusion and in-stent thrombosis in a\u00a0patient with essential thrombocythemia. Cathet Cardiovasc Diagn. 1998;45:428\u201333.","journal-title":"Cathet Cardiovasc Diagn"},{"key":"1757_CR49","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jjcc.2009.03.001","volume":"54","author":"N Kumagai","year":"2009","unstructured":"Kumagai\u00a0N, Mitsutake\u00a0R, Miura\u00a0S, et\u00a0al. Acute coronary syndrome associated with essential thrombocythemia. J\u00a0Cardiol. 2009;54:485\u20139.","journal-title":"J Cardiol"},{"key":"1757_CR50","first-page":"147","volume":"2","author":"U Ayd\u0131n","year":"2016","unstructured":"Ayd\u0131n\u00a0U, Turk\u00a0T, Ata\u00a0Y, Yavuz\u00a0S. Cardiac surgery in patients with essential thrombocytosis: a\u00a0report of three cases. Eur Res\u00a0J. 2016;2:147\u201350.","journal-title":"Eur Res J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-023-01757-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-023-01757-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-023-01757-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T09:47:15Z","timestamp":1725616035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-023-01757-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":50,"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1007\/s12471-023-01757-4","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"6 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S.\u00a0Kuipers, L.\u00a0Kok, R.\u00a0Virmani and A.\u00a0Tefferi declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}